Filing Analysis
Femasys Inc. announced its quarterly financial results for the period ending June 30, 2026, and provided a general corporate update via an 8-K filing.
📋 Key Facts
- Reporting date: August 14, 2026
- Period covered: Quarter ended June 30, 2026
- The filing includes a press release as Exhibit 99.1 containing financial results and corporate updates.
- Company is an emerging growth company.
Femasys Inc. completed a $30 million private placement involving common stock and multiple tranches of warrants, including milestone-based warrants. The deal includes significant board representation rights for the lead investor and requires a registration statement to be filed within 30 days.
🚩 Red Flags
- Significant potential dilution: The total number of shares issuable upon exercise of all warrants is nearly 28 million, significantly exceeding the current common stock issuance.
- Warrant overhang: Large volume of milestone and common warrants can create downward selling pressure.
- Board control shift: Lead investor secured board representation rights via a side letter.
- Registration requirement: The company must file a resale registration statement within 30 days to allow investors to liquidate.
📋 Key Facts
- Gross proceeds from the private placement are approximately $30.0 million.
- Securities issued include 5,013,559 shares of common stock at $3.20 per share.
- Issuance includes pre-funded warrants (4,361,440 shares) and two types of common/milestone warrants totaling 18,749,998 potential shares.
- Milestone warrants trigger upon achieving $1.5M in U.S. revenue in a fiscal quarter AND the stock price maintaining 130% of the exercise price for 20 of 30 trading days.
- Nantahala Capital Management, LLC (Lead Investor) gained rights to appoint up to two board designees via a side letter.
- Five company insiders participated in the offering with an aggregate purchase of ~$134,000.
Femasys Inc. held its Annual Meeting of Stockholders on June 24, 2026, where shareholders elected two Class II directors and ratified KPMG LLP as the independent accounting firm for fiscal year 2026.
🚩 Red Flags
- The filing notes that all vote totals were adjusted to reflect a 1-for-20 reverse stock split effected on June 5, 2026 (a common indicator of potential delisting risk or low share price management).
📋 Key Facts
- Annual Meeting held on June 24, 2026.
- Quorum consisted of 1,487,447 shares, representing approximately 49.26% of total outstanding shares eligible to vote.
- Charles Larsen and Kenneth Eichenbaum were elected to the Board of Directors for three-year terms expiring in 2029.
- KPMG LLP was ratified as the independent registered accounting firm for the fiscal year ending December 31, 2026.
- Voting totals reflect the impact of a 1-for-20 reverse stock split executed on June 5, 2026.
Femasys Inc. has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share. This follows a 1-for-20 reverse stock split executed on June 5, 2026, which resolved the deficiency originally identified in July 2025.
🚩 Red Flags
- History of delisting risk: The company failed to maintain minimum bid price requirements since July 2025.
- Reverse stock split: Executed a 1-for-20 reverse split, which is often viewed as a sign of significant share price erosion.
📋 Key Facts
- Nasdaq confirmed compliance with Listing Rule 5550(a)(2) on June 23, 2026.
- The company regained compliance via a 1-for-20 reverse stock split effective June 5, 2026.
- Compliance was achieved after the stock maintained a bid price of at least $1.00 for 10 consecutive business days post-split.
Femasys Inc. executed a 1-for-20 reverse stock split effective June 5, 2026, to consolidate its outstanding common stock. The split-adjusted shares are scheduled to begin trading on the Nasdaq Capital Market on June 8, 2026.
🚩 Red Flags
- Reverse stock splits are frequently used by micro-cap companies to artificially inflate share price to maintain Nasdaq minimum bid price requirements and avoid delisting.
📋 Key Facts
- Reverse split ratio is 1-for-20.
- Effective date and time: June 5, 2026, at 8:40 a.m. Eastern Time.
- Trading on a split-adjusted basis begins June 8, 2026.
- Fractional shares are rounded up to the next whole share at the DTC participant level.
- New CUSIP number: 31447E 204.
- Stock options, RSUs, and warrants were adjusted proportionately (decrease in shares, increase in exercise price).
Femasys Inc. announced a 1-for-20 reverse stock split of its common stock, effective June 5, 2026, with split-adjusted trading beginning on June 8, 2026.
🚩 Red Flags
- Reverse stock splits in micro-cap companies are frequently used to artificially inflate share price to avoid Nasdaq minimum bid price delisting requirements.
📋 Key Facts
- Reverse split ratio is 1-for-20.
- Effective date: June 5, 2026, at 4:30 p.m. ET.
- Split-adjusted trading begins: June 8, 2026.
- New CUSIP number: 31447E 204.
- Fractional shares will be rounded up to the next whole share at the DTC participant level.
- Trading symbol 'FEMY' remains unchanged.
Femasys Inc. filed an 8-K to disclose an updated corporate slide presentation for use in upcoming meetings with investors and analysts. The presentation was furnished under Item 7.01 and is intended to provide current information to the market.
📋 Key Facts
- Report date: May 13, 2026
- Item 7.01: Regulation FD Disclosure regarding an updated slide presentation
- Exhibit 99.1: Updated corporate presentation for investor and analyst meetings
- The information is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act
Femasys Inc. announced its financial results for the first quarter ended March 31, 2026, and provided a corporate update. The information was furnished via a press release attached as Exhibit 99.1.
📋 Key Facts
- Financial results reported for the quarter ended March 31, 2026
- Corporate update provided in conjunction with financial results
- Filing date: May 8, 2026
- Information furnished under Item 2.02 and not deemed 'filed' for Section 18 purposes
Femasys stockholders approved a reverse stock split of up to 1-for-25 and authorized the issuance of shares exceeding 19.99% of outstanding stock related to convertible notes and warrants. The approvals facilitate significant potential dilution through anti-dilution and price adjustment provisions that may drop below the Nasdaq Minimum Price.
🚩 Red Flags
- Authorization of a significant reverse stock split (up to 1-for-25), often a sign of delisting risk or price distress.
- Approval of highly dilutive share issuances below the Nasdaq Minimum Price.
- Related-party transactions involving directors and officers in the private placements.
- Potential for massive dilution through anti-dilution and price adjustment provisions in convertible notes and warrants.
📋 Key Facts
- Stockholders approved a reverse stock split ratio between 1-for-2 and 1-for-25, to be implemented at the board's discretion before May 1, 2027.
- Approved the issuance of common stock in excess of 19.99% of outstanding shares upon conversion of senior secured convertible notes and exercise of Series A-1, B-1, C-1, and D-1 warrants.
- The issuance approval includes provisions for effective conversion or exercise prices below the Nasdaq Minimum Price.
- The underlying private placements included participation by directors and officers of the company.
- The Special Meeting of Stockholders was held on April 29, 2026, with 39.91% of eligible shares represented.
Femasys Inc. appointed John Canning as Chief Operating Officer, effective March 30, 2026. Mr. Canning, a former COO at Terumo Aortic, will receive a $450,000 base salary and 150,000 inducement stock options.
📋 Key Facts
- John Canning appointed as COO effective March 30, 2026
- Annual base salary of $450,000 with a 40% target bonus
- Inducement grant of 150,000 stock options outside the 2021 Equity Incentive Plan
- Canning previously served as COO at Terumo Aortic (2017-2026) and held roles at Medtronic
- Severance includes 9 months of base salary and COBRA premiums
Femasys Inc. announced its financial results for the fiscal year ended December 31, 2025, and provided a corporate update. The announcement was furnished via a press release on March 31, 2026.
📋 Key Facts
- The filing was made on March 31, 2026, reporting results for the fiscal year ended December 31, 2025.
- The report includes a corporate update in addition to financial results.
- The information is furnished under Item 2.02 (Results of Operations and Financial Condition) and is not deemed 'filed' for statutory purposes.
- Femasys Inc. is identified as an emerging growth company.
Femasys Inc. entered into an omnibus amendment with lenders to remove share combination adjustment provisions in existing convertible notes and warrants, issuing over 16 million new warrants as consideration. Concurrently, the lead lender exercised its contractual right to appoint a new director to the board following a resignation.
🚩 Red Flags
- Issuance of a massive volume of warrants (16,378,563) as consideration for a technical amendment to debt terms.
- Removal of 'Share Combination Event Adjustment' language often signals an impending or recently completed reverse stock split.
- Lender-controlled board seat indicates significant creditor influence over corporate governance.
- Multiple 8-K items (1.01, 3.02, 5.02) triggered in a single filing.
📋 Key Facts
- Entered into an Omnibus Amendment and Consent Agreement on March 19, 2026, with holders of Senior Secured Convertible Notes.
- The amendment removes the 'Share Combination Event Adjustment' in existing Notes and Warrants effective December 31, 2025.
- Issued 16,378,563 Series D-1 Warrants to lenders as consideration for the amendment, with an exercise price of $0.58 per share.
- Director Joshua Silverman resigned effective March 17, 2026.
- Dr. Kenneth D. Eichenbaum was appointed to the Board on March 18, 2026, pursuant to a nomination right held by Pointillist Partners LLC (the Lead Lender).
- Pointillist Partners LLC's nomination right remains active as long as they own at least 4.99% of the company or until the notes are paid in full.
Femasys Inc. has been granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price requirement, which expires on July 13, 2026. The company intends to cure the deficiency, potentially through a reverse stock split, if necessary.
🚩 Red Flags
- Delisting notice/Non-compliance with Nasdaq listing rules
- Potential for a reverse stock split (dilution risk and negative market sentiment)
- Persistent low share price (below $1.00)
📋 Key Facts
- The company was non-compliant with Nasdaq Listing Rule 5550(a)(2) due to the stock price being below $1.00 for 30 consecutive business days.
- Nasdaq granted a 180-day extension on January 13, 2026, moving the compliance deadline to July 13, 2026.
- The company reported over $5 million in stockholders' equity as of December 31, 2025.
- Management explicitly stated they will consider a reverse stock split to meet the minimum bid price requirement.
Femasys Inc. has filed a prospectus supplement to initiate an 'at the market' (ATM) offering of common stock with an aggregate value of up to $9,800,000. The sale will be conducted through Piper Sandler & Co. under an existing Equity Distribution Agreement.
🚩 Red Flags
- Potential dilution for existing shareholders due to the issuance of new common stock.
- ATM offerings are often used by micro-cap companies to raise immediate working capital, which can signal a need for liquidity.
📋 Key Facts
- Aggregate offering price: up to $9,800,000
- Security type: Common Stock (par value $0.001 per share)
- Sales Agent: Piper Sandler & Co.
- Offering method: 'At the market' (ATM) offering pursuant to Rule 415(a)(4)
- Registration basis: Existing Form S-3 Registration Statement (File No. 333-288527)
Femasys Inc. announced that it has received U.S. FDA clearance for its next-generation FemVue diagnostic device. This is a regulatory milestone related to the company's product pipeline.
📋 Key Facts
- FDA clearance obtained for 'Next-Generation FemVue Diagnostic Device'.
- Announcement date: December 18, 2025.
- The filing includes a press release as Exhibit 99.1.
Femasys Inc. announced its financial results for the quarter ended September 30, 2025, and provided a corporate update via an 8-K filing on November 14, 2025.
📋 Key Facts
- Reporting period: Quarter ended September 30, 2025
- Filing date: November 14, 2025
- The company is an emerging growth company
- Financial results and corporate update were released via press release (Exhibit 99.1)
Femasys Inc. announced a significant commercial milestone involving its second partner order for the FemBloc product in Europe. This represents an expansion of their international market presence and revenue potential.
📋 Key Facts
- Company issued a press release on November 10, 2025.
- Announced a 'Second Partner Order' for its FemBloc product specifically in the European market.
- The announcement is categorized under Item 8.01 (Other Events).
Femasys Inc. entered into a $12 million private placement involving senior secured convertible notes and multiple series of warrants. The proceeds are intended to repay existing 2023 debt and provide working capital.
🚩 Red Flags
- High dilution risk due to significant number of shares issuable via notes and warrants.
- Senior secured debt: The new notes are secured by a lien on substantially all company assets, including IP.
- PIK Interest: 8.50% interest is payable in-kind (increasing the principal), which compounds the debt burden.
- Board control shift: Lead Lender has rights to nominate a Board member and an observer.
- Potential for significant downward pressure on stock price upon registration of shares.
📋 Key Facts
- Total expected gross proceeds: $12,000,000.
- Two closing dates scheduled for November 7, 2025, and November 26, 2025.
- Securities include senior secured convertible notes with an 8.50% interest rate (payable in-kind) maturing in 10 years.
- Conversion price set at $0.73 per share, representing a 15% premium to the prior closing price.
- Warrants issued: Series A-1 ($0.81), Series B-1 ($0.92), and Series C-1 ($1.10).
- The notes are secured by a lien on substantially all of the Company's assets.
- Lead Lender (Pointillist Global Macro Series) gains one Board seat and one non-voting observer right.
Femasys Inc. announced a significant regulatory milestone regarding FDA approval for its FemBloc trial phase and secured $12 million in financing, with potential total funding reaching $58 million.
🚩 Red Flags
- The need for significant external financing ($12M secured, $46M more potentially required) suggests ongoing cash burn typical of clinical-stage biotech companies.
📋 Key Facts
- FDA approval obtained to advance the final phase of the FemBloc clinical trial.
- Secured $12 million in immediate financing.
- Total potential financing amount cited is up to $58 million.
- Filing date: November 3, 2025.
Femasys Inc. reports that it has addressed its Nasdaq delisting notice regarding the Minimum Market Value of Listed Securities (MVLS) by meeting the alternative stockholders' equity requirement. The company expects pro forma stockholders' equity to be approximately $5.2 million as of October 15, 2025, surpassing the $2.5 million minimum standard.
🚩 Red Flags
- Delisting notice (non-compliance with MVLS requirement)
- History of failing multiple Nasdaq listing standards
- Reliance on equity financing/warrant exercises to meet minimum capital requirements
📋 Key Facts
- The company received a Nasdaq notice on May 19, 2025, due to MVLS falling below $35.0 million for 30 consecutive business days.
- Company failed both alternative standards: stockholders' equity < $2.5M and net income < $500k in recent fiscal years.
- Following an $8.0 million underwritten offering (filed Aug 27, 2025) and subsequent warrant exercises, pro forma stockholders' equity is estimated at ~$5.2 million as of Oct 15, 2025.
- Compliance will be monitored by Nasdaq and must be evidenced in the next periodic report to avoid delisting.
Femasys Inc. announced the retirement of its Chief Operating Officer, Daniel Currie, effective December 15, 2025. The departure is attributed to personal health and family reasons following a 20-year tenure with the company.
🚩 Red Flags
- Departure of a long-tenured executive (20+ years) can lead to institutional knowledge loss.
📋 Key Facts
- Daniel Currie (COO) will retire effective December 15, 2025.
- Mr. Currie has been with the company since March 2004.
- A Separation and General Release Agreement was entered into on October 16, 2025.
- Unvested stock options will vest through the retirement date.
- Health benefits will continue under COBRA through December 31, 2026.
Femasys Inc. entered into an underwriting agreement for a public offering of 10,434,586 shares of common stock and various warrants to raise approximately $8.0 million in gross proceeds. The offering is priced at a significant discount relative to typical market valuations, involving pre-funded warrants and common warrants.
🚩 Red Flags
- Significant dilution potential due to the issuance of over 34 million total warrants/shares in connection with a small capital raise.
- Extremely low exercise price ($0.0001) on pre-funded warrants, which is highly dilutive to existing shareholders.
- Low share price ($0.36) suggests potential liquidity or survival-driven financing (death spiral characteristics).
- Heavy use of warrants as part of the consideration.
📋 Key Facts
- Gross proceeds expected: $8.0 million (before expenses).
- Common stock offered: 10,434,586 shares at $0.36 per share (with some officer shares at $0.5151).
- Pre-funded warrants: 11,750,000 warrants to purchase shares at an exercise price of $0.0001.
- Common warrants: 22,184,586 warrants with a 5-year expiration and $0.36 exercise price.
- Underwriters: JonesTrading Institutional Services LLC and Laidlaw & Company (UK) Ltd.
- Closing date expected: August 27, 2025.
Femasys Inc. announced that it has secured UK regulatory approval for its FemBloc Permanent Birth Control product. This is a positive regulatory development for the company's international market expansion.
📋 Key Facts
- Company received UK regulatory approval for 'FemBloc Permanent Birth Control'.
- Announcement made via press release on August 20, 2025.
- The filing includes Exhibit 99.1 containing the full press release.
Femasys Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2025, and provided a general corporate update via a press release.
📋 Key Facts
- Report date: August 8, 2025
- Reporting period: Quarter ended June 30, 2025
- The filing includes the announcement of financial results and a corporate update
- Company is an emerging growth company
Femasys Inc. announced the securing of its first European order for its FemBloc product. This represents a strategic milestone in the company's international market expansion efforts.
📋 Key Facts
- Date of event: August 6, 2025
- Company secured its first European order for 'FemBloc'.
- The announcement is categorized as a strategic milestone for global expansion.
Femasys Inc. received a notice from Nasdaq stating it is non-compliant with the minimum bid price requirement after its stock traded below $1.00 for 30 consecutive business days. The company has until January 12, 2026, to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice from Nasdaq
- Stock price has been below $1.00 for 30 consecutive business days
- Potential requirement for a reverse stock split to maintain listing
📋 Key Facts
- Received Nasdaq notice on July 16, 2025.
- Non-compliance with Nasdaq Listing Rule 5550(a)(2) due to minimum bid price requirement.
- The company has a 180-day grace period ending January 12, 2026, to regain compliance.
- To regain compliance, the stock must trade at or above $1.00 for at least ten consecutive business days during the grace period.
- A second 180-day compliance period may be available if a reverse stock split is used as a cure.
Femasys Inc. entered into an 'Any Market Purchase Agreement' (AMPA) with Alumni Capital LP, allowing the company to sell up to $10 million in common stock through 2026. This structure functions as a highly dilutive equity line of credit where the purchaser buys shares at significant discounts to market price.
🚩 Red Flags
- Highly dilutive financing structure (selling shares at 3-10% discounts to market price).
- The 'Any Market' nature of the agreement can create downward pressure on the stock price as the purchaser sells into the market.
- Requirement to file an S-1 registration statement by July 30, 2025, indicating immediate need for liquidity.
📋 Key Facts
- Entered into an AMPA with Alumni Capital LP on June 30, 2025.
- Total investment amount: up to $10 million in common stock.
- Purchase Price Option 1: Lowest traded price for the previous four business days multiplied by 90%.
- Purchase Price Option 2: Lesser of $1M or 100% of average daily trading volume (two-day VWAP) multiplied by 97%.
- Company must pay a 2% commitment fee in cash.
- Includes an exchange cap preventing the purchaser from owning more than 19.99% without shareholder approval.
Femasys Inc. announced regulatory approvals in Australia and New Zealand for two products: FemaSeed (infertility treatment) and FemVue (diagnostic). The filing serves to furnish a press release regarding these clinical/regulatory milestones.
📋 Key Facts
- Regulatory approval achieved in Australia and New Zealand for FemaSeed (First-Line Infertility Treatment).
- Regulatory approval achieved in Australia and New Zealand for FemVue Diagnostic.
- The announcement was made via a press release dated July 1, 2025.
Femasys Inc. held its Annual Meeting of Stockholders on June 25, 2025, where shareholders approved the election of two directors and an amendment to the equity incentive plan. The meeting also included the ratification of KPMG LLP as the independent accounting firm.
📋 Key Facts
- Annual Meeting held on June 25, 2025, with 16,183,538 shares (approx. 59.41% of outstanding) represented in person or by proxy.
- Alistair Milnes and Edward Uzialko were elected to the Board of Directors for three-year terms expiring in 2028.
- Stockholders approved an amendment to the 2021 Equity Incentive Plan to increase authorized shares by 3,000,000.
- KPMG LLP was ratified as the independent registered accounting firm for fiscal year ending December 31, 2025.
Femasys Inc. announced a significant regulatory milestone regarding the European approval of FemBloc, described as the first non-surgical permanent birth control.
📋 Key Facts
- Announcement date: June 25, 2025
- Product name: FemBloc
- Regulatory achievement: European Approval
- Product classification: First Non-Surgical Permanent Birth Control
Femasys Inc. announced the appointment of Ms. Nicholas as its new Chief Commercial Officer on June 17, 2025.
📋 Key Facts
- Appointment of Ms. Nicholas to the role of Chief Commercial Officer (CCO).
- Announcement date: June 17, 2025.
- The company is an emerging growth company.
Femasys Inc. announced a multi-pronged financing effort including an underwritten public offering of 3.6 million shares and a concurrent private placement to institutional investors and insiders. The company is also seeking a $10 million equity line of credit, facing potential liquidated damages if not secured by June 30, 2025.
🚩 Red Flags
- Significant dilution: Issuance of over 5 million new shares at a low price point ($0.85).
- Liquidity pressure: The company is actively seeking an equity line of credit to avoid $400,000 in liquidated damages by June 30.
- Warrant overhang: Issuance of warrants to the underwriter may create further dilution and selling pressure.
📋 Key Facts
- Underwritten public offering: 3,600,000 shares at $0.85 per share.
- Underwriter option to purchase up to 540,000 additional shares.
- Private placement: 1,588,235 shares at $0.85 (institutional) and 98,040 shares at $1.02 (directors/officers).
- Expected gross proceeds from combined offerings: $4.5 million.
- Estimated net proceeds to company: approximately $4.2 million.
- Underwriter warrants issued for 105,726 shares with an exercise price of $1.0625.
- Agreement in principle for a $10 million equity line of credit with Alumni Capital LP by June 30, 2025; failure to execute results in a $400,000 penalty.
Femasys Inc. received a notice from Nasdaq stating it is in violation of the Minimum Market Value of Listed Securities (MVLS) requirement. The company has 180 days to regain compliance before facing potential delisting.
🚩 Red Flags
- Delisting notice from Nasdaq (Rule 5550(b)(2)).
- Failure to meet alternative listing standards regarding stockholders' equity and net income.
- Market capitalization/MVLS is significantly below the required $35M threshold.
📋 Key Facts
- Received written notice from Nasdaq on May 19, 2025.
- Violation: MVLS was below the $35.0 million minimum for 30 consecutive business days.
- Company failed alternative standards: Stockholders' equity < $2.5M and Net Income < $500k in recent fiscal years.
- Compliance deadline: November 17, 2025 (180-day grace period).
- Current status: Common stock remains listed under symbol 'FEMY'.
Femasys Inc. announced its financial results for the quarter ended March 31, 2025, and provided a corporate update via an 8-K filing on May 8, 2025.
📋 Key Facts
- Reporting period: Quarter ended March 31, 2025
- Filing date: May 8, 2025
- The report includes a press release (Exhibit 99.1) detailing financial results and a corporate update.
- Company is an emerging growth company.
Femasys Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2024, and provided a corporate update via a press release.
📋 Key Facts
- Report date: March 27, 2025
- Reporting period: Fiscal year ended December 31, 2024
- The filing includes results of operations and financial condition updates (Item 2.02)
- Company is an emerging growth company
Femasys Inc. announced the securing of distribution partnerships to commercialize its FemBloc product in Spain. The filing serves as a formal announcement of these international expansion efforts.
📋 Key Facts
- Date of event: March 18, 2025
- Product involved: FemBloc
- Geographic focus: Spain
- Nature of event: Secured distribution partnerships for commercialization
Femasys Inc. announced the regulatory approval of its FemBloc delivery system in Europe. This marks a significant milestone for the company's non-surgical permanent birth control product line.
📋 Key Facts
- On March 13, 2025, Femasys Inc. received European approval for its FemBloc delivery system.
- The FemBloc system is positioned as a first-of-its-kind non-surgical approach to permanent birth control.
- The announcement was made via an official press release (Exhibit 99.1).
This is an amendment to a previously filed 8-K (Form 8-K/A) intended solely to correct clerical errors regarding reporting dates. The company corrected the 'Date of Report' and the date referenced in Item 2.02 from August 12, 2024, to November 12, 2024.
📋 Key Facts
- The filing is an amendment (8-K/A) to an original 8-K filed on November 12, 2024.
- Purpose of filing: To correct incorrect dates in the cover page and Item 2.02.
- Corrected date for 'Date of Report' is November 12, 2024.
- The original error incorrectly cited August 12, 2024, as the earliest event reported.
Femasys Inc. filed an 8-K to furnish its financial results for the quarter ended September 30, 2024 and provide a corporate update via press release.
📋 Key Facts
- The filing is related to Item 2.02 (Results of Operations and Financial Condition).
- Financial results were announced on August 12, 2024 (Note: Filing date/Report date discrepancy in text suggests a potential typo or forward-looking reporting cycle).
- A press release dated November 12, 2024 is attached as Exhibit 99.1.
Femasys Inc. filed an 8-K to provide notice of the posting of an updated corporate presentation on its website. This filing is intended for use in investor and analyst meetings.
📋 Key Facts
- The company posted an updated slide presentation dated October 2024 (Exhibit 99.1).
- The information provided under Item 7.01 is furnished but not 'filed' for purposes of Section 18 liabilities.
- The presentation will be used in meetings with investors, analysts, and other parties.
Femasys Inc. announced the securing of strategic distribution partnerships for its FemaSeed product in the Spanish market, representing over $1.3 million in potential value.
📋 Key Facts
- Secured strategic distribution partnerships for commercialization of FemaSeed.
- The agreements are valued at over $1.3M in the Spanish market.
- Announcement date: September 11, 2024.
Femasys Inc. announced that it has received U.S. FDA clearance for FemChec, a diagnostic solution designed for fallopian tube checks. This represents a regulatory milestone for the company's product pipeline.
📋 Key Facts
- FDA clearance granted for 'FemChec', a diagnostic solution for fallopian tube check.
- Announcement date: September 9, 2024.
- The filing is an Item 8.01 (Other Events) disclosure.
Femasys Inc. filed an 8-K to provide notice of an updated corporate presentation posted on its website. This is a routine disclosure under Regulation FD intended for use in investor meetings and analyst discussions.
📋 Key Facts
- The company updated its corporate slide presentation on August 30, 2024.
- The presentation is attached as Exhibit 99.1.
- The information is furnished under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for purposes of Section 18 liability.
Femasys Inc. announced the receipt of CE Mark and Canadian regulatory approval for its FemVue MINI fallopian tube assessment solution. This represents a positive regulatory milestone for the company's product portfolio.
📋 Key Facts
- Received CE Mark (European Union) for FemVue MINI on August 29, 2024.
- Received Canadian regulatory approval for FemVue MINI on August 29, 2024.
- FemVue MINI is a fallopian tube assessment solution.
Femasys Inc. announced its financial results for the second quarter ended June 30, 2024, and provided a general corporate update via an 8-K filing.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2024
- Announcement date: August 8, 2024
- The filing includes results of operations and financial condition under Item 2.02
- Company is classified as an emerging growth company
Femasys Inc. held its Annual Meeting of Stockholders on July 12, 2024. The meeting resulted in the successful election of a new director and the ratification of KPMG LLP as the company's independent accounting firm.
📋 Key Facts
- Annual Meeting held on July 12, 2024, with approximately 48.2% of outstanding shares represented (10,703,636 shares).
- Kathy Lee-Sepsick was elected to the Board of Directors for a three-year term expiring in 2027.
- Stockholders ratified the appointment of KPMG LLP as the independent registered accounting firm for the fiscal year ending December 31, 2024.
Femasys Inc. announced it has received CE Mark approval for four of its women's health products. This regulatory milestone enables the company to begin commercialization efforts in the European market.
📋 Key Facts
- Received CE Mark approval for four women's health products on June 20, 2024.
- Approval clears the path for commercialization in Europe.
- The announcement was made via a press release furnished as Exhibit 99.1.
Femasys Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2024, and provided a corporate update via a press release.
📋 Key Facts
- Reporting period: First Quarter ended March 31, 2024.
- Filing date: May 9, 2024.
- The filing includes results of operations and financial condition updates (Item 2.02).
- Company is an emerging growth company.
Femasys Inc. filed an 8-K to provide notice of an updated corporate presentation posted on its website. This filing is intended for use in investor and analyst meetings.
📋 Key Facts
- The company released an updated slide presentation dated April 24, 2024 (Exhibit 99.1).
- The information provided under Item 7.01 is furnished but not considered 'filed' for purposes of Section 18 liabilities.
- The company disclaims any obligation to update or revise the presentation in the future.
Femasys Inc. filed an 8-K to announce its full-year financial results for the fiscal year ended December 31, 2023, and provided a corporate update via a press release.
📋 Key Facts
- Reporting date: March 28, 2024
- Financial period covered: Year ended December 31, 2023
- The filing includes an announcement of financial results and a corporate update via Exhibit 99.1.
Femasys Inc. issued a press release announcing positive topline data from its pivotal trial of the FDA-cleared FemaSeed device for infertility treatment.
📋 Key Facts
- Announcement date: March 20, 2024
- Subject: Positive topline data from a pivotal clinical trial
- Product: FemaSeed (FDA-cleared)
- Indication: Treatment of infertility
Femasys Inc. announced the successful completion of its first in-office commercial procedure using its FDA-cleared FemaSeed infertility solution on March 6, 2024.
📋 Key Facts
- Completion of the first in-office commercial procedure with FemaSeed.
- FemaSeed is an FDA-cleared infertility solution.
- The announcement was made via press release dated March 6, 2024.
Femasys Inc. filed an 8-K to provide updated corporate presentation materials and announce the FDA clearance of its FemaSeed product, a first-line infertility treatment alternative to IVF.
📋 Key Facts
- Company posted an updated slide presentation on its website (Exhibit 99.1).
- Announced FDA clearance for 'FemaSeed', positioned as an alternative to In Vitro Fertilization (IVF).
- The filing includes a press release regarding the FemaSeed regulatory milestone (Exhibit 99.2).
Femasys Inc. announced the appointment of Mr. Spector as the company's new Chief Commercial Officer via a press release on February 6, 2024.
📋 Key Facts
- Appointment of Mr. Spector as Chief Commercial Officer (CCO).
- Announcement date: February 6, 2024.
- The filing includes an exhibit (99.1) containing the full press release regarding this leadership change.